1. Ex-vivo mucolytic and anti-inflammatory activity of BromAc in tracheal aspirates from COVID-19.
- Author
-
Coelho Dos Reis JGA, Ferreira GM, Lourenço AA, Ribeiro ÁL, da Mata CPDSM, de Melo Oliveira P, Marques DPA, Ferreira LL, Clarindo FA, da Silva MF, Filho HPP, Oliveira NRR Jr, Sodré MMD, Gadelha SR, Albuquerque GR, Maciel BM, Mariano APM, Silva MM, Fontana R, Marin LJ, Carlos RSA, Lopes ATS, Ferreira FB, Dos Santos UR, Santana ÍTS, Fehlberg HF, Rezende RP, Dias JCT, Gross E, Goulart GAC, Santiago MG, de Lemos APML, da Conceição AO, Romano CC, de Carvalho LD, Martins Filho OA, Quadros CA, Morris DL, and Valle SJ
- Subjects
- Acetylcysteine administration & dosage, Adolescent, Adult, Aged, Aged, 80 and over, Anti-Inflammatory Agents administration & dosage, Anti-Inflammatory Agents pharmacology, Bromelains administration & dosage, Cytokine Release Syndrome pathology, Dose-Response Relationship, Drug, Down-Regulation, Drug Combinations, Expectorants pharmacology, Female, Humans, Inflammation Mediators metabolism, Male, Middle Aged, Respiration, Artificial, Rheology, SARS-CoV-2, Trachea pathology, Young Adult, Acetylcysteine pharmacology, Bromelains pharmacology, COVID-19 pathology, Chemokines drug effects, Cytokines drug effects, Sputum cytology
- Abstract
COVID-19 is a lethal disease caused by the pandemic SARS-CoV-2, which continues to be a public health threat. COVID-19 is principally a respiratory disease and is often associated with sputum retention and cytokine storm, for which there are limited therapeutic options. In this regard, we evaluated the use of BromAc®, a combination of Bromelain and Acetylcysteine (NAC). Both drugs present mucolytic effect and have been studied to treat COVID-19. Therefore, we sought to examine the mucolytic and anti-inflammatory effect of BromAc® in tracheal aspirate samples from critically ill COVID-19 patients requiring mechanical ventilation., Method: Tracheal aspirate samples from COVID-19 patients were collected following next of kin consent and mucolysis, rheometry and cytokine analysis using Luminex kit was performed., Results: BromAc® displayed a robust mucolytic effect in a dose dependent manner on COVID-19 sputum ex vivo. BromAc® showed anti-inflammatory activity, reducing the action of cytokine storm, chemokines including MIP-1alpha, CXCL8, MIP-1b, MCP-1 and IP-10, and regulatory cytokines IL-5, IL-10, IL-13 IL-1Ra and total reduction for IL-9 compared to NAC alone and control. BromAc® acted on IL-6, demonstrating a reduction in G-CSF and VEGF-D at concentrations of 125 and 250 µg., Conclusion: These results indicate robust mucolytic and anti-inflammatory effect of BromAc® ex vivo in tracheal aspirates from critically ill COVID-19 patients, indicating its potential to be further assessed as pharmacological treatment for COVID-19., (Copyright © 2022 The Authors. Published by Elsevier Masson SAS.. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF